DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS
|
|
- Bryce King
- 6 years ago
- Views:
Transcription
1 GLOBAL PROVIDER, LOCAL SOLUTIONS IN YOUR LANGUAGE DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS Francesco Amorosi PhD Octorber 2017
2 DATA INTEGRITY & CSV: REGULATORY BACKGROUND
3 MEDICINES AND QUALITY OF MEDICINES: ONE POINT OF VIEW ULTIMATE TARGET OF GXP Ensure the Product Quality and Patient Safety within the entire Product Life Cycle from R&D to Distribution 3
4 GLOBALIZATION: NEW CHALLENGES FOR REGULATORS Globalization has fundamentally changed the economic and security landscape : Advances in transportation, telecommunications, infrastructure More outsourcing manufacturing Greater complexity in supply chain Imports coming from countries with less developed regulatory systems Computer Systems and New Technologies are more and more supporting any Actor of the Supply Chain All this demands a major improvement in the way Regulators/Drug Products Manufacturers, Distributors, Suppliers fulfill their mission. 4
5 QUALITY IN 21 ST CENTURY CREATE GLOBAL COALIZATION (to avoid rules interpretation and rely on each others ) PIC/S membership in continuous expansion Inspectional Cooperation Program Jointly announced by FDA & EMA in 2011 (Now in extension and maintenance phase) Formal incorporation of ICH Quality Guidelines into assessor/inspector guidelines (both EU and US Sides) FIGHT COUNTERFEIT Serialization & Aggregation Requirements RELY ON DATA Focus on DATA INTEGRITY (QC and Production) 5
6 DATA INTEGRITY ISSUES PLAGUE OVERSEAS DRUGMAKERS 1/2 Data integrity issues were the most striking findings included in the Office of Manufacturing Quality s 2015 annual report of warning letters. FDA investigators found data manipulation, cover-ups with faked test results, uneven paper trails, destroyed or misplaced records, backdated production reports. The warning letters note problems such as failure of the quality unit to ensure: materials are appropriately tested and the results reported, lack of appropriate controls for batch records, lack of controls for documentation. Moreover, data integrity issues uncovered during an inspection were almost always red flags for larger quality control problems, warning letters indicate 6
7 DATA INTEGRITY ISSUES PLAGUE OVERSEAS DRUGMAKERS 1/2 Each warning letter singled out unauthorized access or changes to data and failure to prevent data omission. The FDA also wants to see detailed management strategies and procedures for getting at root causes of data integrity practices affecting the quality of drug products. Data integrity lapses have become so widespread globally, that even the World Health Organization stepped in last year to issue guidance to bridge the gaps between the principles of good data and record management and actual practices. Most of the letters urged companies to hire a third-party consultant with expertise in data integrity and GMP issues, and drugmakers were urged to review their entire organizational structure and personnel responsibilities. 7
8 DATA INTEGRITY EXPERTS FDA expectations on the role of the Data Integrity Expert Gapless identification (electronic data have been recorded and documented incorrectly). Identification and interview of all employees [ ] and the management which contributed to or caused the GMP deviations. Supporting indications of GMP non-compliant handling of electronic data should be identified. It must be revealed to what extent the top and middle management knew about or was involved in the data manipulation. The data integrity expert should find out whether managers are still able to have an influence on the integrity of GMP relevant data. Internal reviews are to be extended to other sites which are known to be involved in violations of GMP-compliant handling of data 8
9 REQUIREMENTS FOR REGULATED DATA REGULATORY EXPECTATION DATA INTEGRITY The extent to which all data are complete, consistent and accurate throughout the data lifecycle, i.e. from initial data generation and recording through processing (including transformation or migration), use, retention, archiving, retrieval and destruction. Where DATA are generated and used to made GxP quality decisions, ensure it is TRUSTWORTHY and RELIABLE YOUR GxP RECORDS REQUIRED TO BE ALCOA 9
10 WHY DATA INTEGRITY MIGHT BE VIOLATED IN YOUR COMPANY (Anil Sawant- PDA Europe - Data Integrity Workshop - London, 2016) 10
11 POTENTIAL ROOT CAUSE FOR DATA INTEGRITY VIOLATIONS POTENTIAL ROOT CAUSE FOR DATA INTEGRITY VIOLATIONS Business Pressure No Awareness Poor Quality Culture Obsolete / Inadequate Automation Vulnerable Process DATA INTEGRITY VIOLATIONS STATS 80% 20 % Unintentional Intentional 11
12 REACTION OF REGULATED AGENCIES o Increase in number and severity of DI findings by almost every Regulated Agency o Impact to public health o Increased focus OBSERVED STATUS REACTION GxP Data Integrity Definitions and Guidance Guidance on good data and record management practices Data Integrity and compliance with CGMP (draft) Guidance on data Integrity (draft) Records and Data Integrity GUIDE V1 Mar (V2 Jul. 2016) Sept Apr Aug Mar t 12
13 DATA INTEGRITY FOUNDATIONS
14 DATA INTEGRITY GOVERNANCE SYSTEM The Data Governance System will be oriented to establish the Directives to ensure the Integrity of Regulated Data created and maintained by the company for Regulated purposes 14
15 DATA GOVERNANCE SYSTEM FOUNDATION Data Governance Establishment Plan Data Integrity Policy Code of ethics Computer System Policy Training Program Data Integrity Assessment Procedure Audit Trail Review procedure 15
16 DATA GOVERNANCE ESTABLISHMENT PLAN Purpose: Design the Governance System to demonstrate effective data governance practices including the necessity for a combination of appropriate organizational culture and behaviors and an understanding of data criticality, data risk and data lifecycle. This will include: communication of expectations to personnel at all levels within the organization in a manner organizational controls: Procedures, Training Program for Management and staff, Documented authorization for data generation and approval, Routine data verification; Periodic surveillance technical controls: Computerized system control and Automation Both long term and interim measures should be implemented to mitigate risk, and will be monitored for effectiveness. Responsibilities: High management 16
17 DATA INTEGRITY POLICY DI Policy establishes the general approach for GxP data integrity created and maintained by the company. Purpose: set forth the activities to assure the completeness, consistency and accuracy of all data generated in GxP impacting areas and facilities according to the regulatory requirements and to ensure that Regulated data are: attributable, legible, contemporaneous, original and accurate. Responsibilities: High management 17
18 COMPUTER SYSTEM POLICY CS Policy establishes the general approach for implementing, maintaining use of, and retirement of computerized systems in GxP regulated environments Purpose: ensure any CS, IT equipment/service GxP critical is validated or qualificated prior to it use and maintained in a valid state throughout the system lifecycle, together the assurance of data integrity Responsibilities: Management, BPO, TO, QA, IT 18
19 TRAINING PROGRAM Establish a standard approach (methods and responsibilities) for the training Each personnel should be adequately trained in order to fulfil their duties and responsibilities according to their job description guaranteeing to have the knowledge and skills required to perform tasks. Responsibilities: QA 19
20 AUDIT TRAIL REVIEW PROCEDURE The Audit Trail Review is a process to assure that activities related to a system and modifications to the data are executed in a controlled manner, ensuring the integrity of the data managed by the system. Purpose: to define the strategy and methodology to execute the Audit Trail Review assuring data integrity and compliance with the applicable rules. Responsibilities: BO, QA, Supervisor, Application manager, IT, Validation System which manages RER and used to release Finished Products YES Class 1 AUDIT TRAIL REVISION WEEKLY with AQL 1.5 NO - System which manages RER supporting the batch release of Raw Materials or Intermediate Products - System which manages RER supporting Stability Studies - System which manages RER with direct impact on product Quality YES Class 2 AUDIT TRAIL REVISION MONTHLY with AQL 4.0 Revision of the Audit Trail frequency and/ or AQL by QA and Business Owner, increasing or decreasing the conditions based on the identified recurrent deviations and/or anomalies NO Class 3 AUDIT TRAIL REVISION ANNUALLY with AQL
21 COMPUTER VALIDATION LIFE CYCLE PROCEDURE PACKAGE IT Infrastructure Qualification Life Cycle Computer Validation Life Cycle Procedure Supporting Processes Security Management Backup & Restore Archiving Business Continuity System Inventory Management Supplier Assessment Computerized Systems Risk Management Retirement Periodic Review Incident Management Change and Configuration Management 21
22 IT INFRASTRUCTURE QUALIFICATION LIFE CYCLE Demonstrate that infrastructure components (networks, servers, clients, server rooms, software tools) are able to meet the related technical requirements Purpose: defined process for the qualification IT Infrastructure supporting GxP computerized systems, which shall be based on actual risks and regulatory compliance. Responsibilities: IT, QA 22
23 ALCOA ASSESSMENT ELECTRONIC RECORDS CASE STUDY
24 DATA INTEGRITY GOVERNANCE ROADMAP DATA INTEGRITY GOVERNANCE PROCESS INVENTORY PROCESS PRIORITY RANK PROCESS MAPPING & DATA LIFE CYCLE GMP RECORDS INVENTORY LIST OF BUSINESS PROCESSES RISK-BASED PRIORITY ASSOCIATED TO EACH MACROPROCESS PROCESS STEPS ASSOCIATED TO EACH BUSINESS PROCESS & DATA LIFE CYCLE LIST OF GMP RECORDS (BOTH PAPER AND ELECTRONIC) 5 RECORD CLASSIFICATION DETERMINATION OF RECORD CRITICALITY AND TYPE 6 ALCOA GAP ANALYSIS Electronic ALCOA Gap Analysis Paper ALCOA Gap Analysis GAPS AGAINST THE ALCOA REQUIREMENTS 7 INTEGRITY EXPOSURE EVALUATION OF EXPOSURE OF RECORDS TO INTEGRITY VIOLATIONS DETERMINED UPON THE OBSERVED GAPS 8 REMEDIATION PLAN RISK BASED & PRIORITY DRIVEN REMEDIATION PLAN 24
25 REMEDIATION PLAN Risk-based and priority-driven remediation actions Short, Medium and Long remediation phases Finalization Deadline: Q1, 2016 Finalization Deadline: Q2, 2016 Finalization Deadline: Q3, 2016 Computerized Systems Assessment Report & Remediation Plan (present document) SHORT TERM: Remediation Very High Risk systems MEDIUM TERM: Remediation High Risk systems LONG TERM: Remediation Medium and Low Risk systems TIME FRAME 25 25
26 Qualification Plan Risk Assessment User Requirements Specifications Design Specifications Functional Specifications Configuration Specifications System Build User Acceptance Tests Integration Tests Module Tests System Tests Configuration Tests Qualification Report Traceability Matrix HOW TO MEET REGULATORY EXPECTATIONS PAST REMEDIATION FUTURE Assess Historical Data in case the current status is observed as deficient Data integrity technical measures SOPs & CSV to ensure system reliability Planning Reporting SPECIFICATIONS TESTING ONGOING Requirements and Specifications Definition Testing 0 t0 t Reliable Data 26
27 CONCLUSIONS
28 NOT (ONLY) A TECHNOLOGY MATTER Technologies change our way of working, but the need of Quality Requirements (GxP) remains the same In both the cases Data Integrity must be assured 28
29 CORRELATED COMPONENTS All Data Integrity components (and relevant Compliance Requirements) are essential EVERY ASPECT NOT PROPERLY HANDLED MAY RESULT IN FAILURE USER PROFILES ACCESS CONTROL 29
30 WHERE WE ARE HEADED Globalization has driven the need to create common standards which rely upon the Integrity of GxP data The monitoring of GxP compliance applies to the entire R&D, Manufacturing and Distribution chain Creating a Culture of Quality is the best way to ensure Data Integrity Computer Validation purpose shall be targeted not to technology but to ensure Data Integrity The status of compliance related to Data Integrity must be documented in the present, analyzed with respect to the past and maintained in the future 30
31 GLOBAL PROVIDER, LOCAL SOLUTIONS IN YOUR LANGUAGE
CUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)
21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software
More informationEU Annex 11 US FDA 211, 820, 11; other guidelines Orlando López 11-MAY-2011
Principle. a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill
More informationDeveloping a Robust Quality System to Assure Data Integrity
Developing a Robust Quality System to Assure Data Integrity Maryann Gribbin Chief Compliance Officer, Faith & Royale Consultants Co-Chair PDA Data Integrity Task Force Data Integrity Facts or information
More informationCOMPUTERISED SYSTEMS
ANNEX 11 COMPUTERISED SYSTEMS PRINCIPLE This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components
More informationGxP Auditing, Remediation, and Quality System Resourcing
GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7
More informationReferences Concept. Principle. EU Annex 11 US FDA , (g), (i), 11 Orlando Lopez 2/15/11. Old Annex 11.
References Concept Principle a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 08 April 2008 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationRegulatory Overview Annex 11 and Part 11. Sion Wyn Conformity +[44] (0)
Regulatory Overview Annex 11 and Part 11 Sion Wyn Conformity +[44] (0) 1492 642622 sion.wyn@conform-it.com 1 Two Key Regulations Annex 11 21 CFR Part 11 Apply to the regulated company, but often have a
More informationGlobal Compliance Trends and Warning Letters
Contact: Charles Lu Director, Quality Carlsbad Tech Phone: (760) 431-8284 Fax: (203) 555-0101 5928 Farnsworth Ct Carlsbad, CA, 92008 www.carlsbadtech.com Global Compliance Trends and Warning Letters Governance
More informationUnderstanding GxP Regulations for Healthcare
Understanding GxP Regulations for Healthcare GxP Guidelines What is GxP? GxP is a collection of quality guidelines and regulations created to ensure that bio/pharmaceutical products are safe, meet their
More informationEU GMP - Annex 11 Computerised systems Versione corrente Nuova versione per commenti (emessa 8 aprile 2008)
EU GMP - Annex 11 Computerised systems Versione corrente Nuova versione per commenti (emessa 8 aprile 2008) Principle The introduction of computerised systems into systems of manufacturing, including storage,
More informationLEVERAGING YOUR VENDORS TO SUPPORT DATA INTEGRITY:
LEVERAGING YOUR VENDORS TO SUPPORT DATA INTEGRITY: QUESTIONS TO ASK AND RESPONSIBILITIES TO DOCUMENT Heather Longden Boston Chapter Educational Meeting April 2018 About Waters Lab Informatics Separations
More informationStrategies for Risk Based Validation of Laboratory Systems
Strategies for Risk Based Validation of Laboratory Systems Video Web Seminar September 23, 2004 Ludwig Huber E-mail: ludwig_huber@agilent.com Today s Agenda Background information: why risk assessment,
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationSIMATIC IT. SIMATIC IT R&D SUITE V7.1 Compliance Response ERES. Introduction 1. The Requirements in Short 2
Introduction 1 The Requirements in Short 2 SIMATIC IT Meeting the Requirements with SIMATIC IT R&D Suite V7.1 3 SIMATIC IT R&D SUITE V7.1 Evaluation List for SIMATIC IT R&D Suite V7.1 4 Product Information
More informationData Reliability - Internet
Data Reliability - Internet Wikipedia https://en.wikipedia.org/wiki/reliability_of_wikipedia Others http://www.dailymail.co.uk/health/article- 2639910/Do-NOT-try-diagnose-Wikipedia-90-medicalentries-inaccurate-say-expertsDo.html
More informationIntroduction to 21 CFR 11 - Good Electronic Records Management
INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY, BIOLOGY AND CHEMISTRY Review Article Introduction to 21 CFR 11 - Good Electronic Records Management Pal Tapas Kumar* and Maity Subhasis NSHM Knowledge Campus,
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationQuality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals
Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality
More informationCSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017
CSV Inspection Readiness through Effective Document Control Eileen Cortes April 27, 2017 Agenda Background CSV Readiness CSV and Change Management Process Inspection Readiness Do s and Don ts Inspection
More informationComputerised Systems. Alfred Hunt Inspector. Wholesale Distribution Information Day, 28 th September Date Insert on Master Slide.
Computerised Systems Wholesale Distribution Information Day, Alfred Hunt Inspector Date Insert on Master Slide Slide 1 Index What is a computerised system Updates to EU GDPs Expectations Case studies Slide
More informationEnsure Data Integrity Compliance in the Analytical Laboratory A Life Cycle Approach
Ensure Data Integrity Compliance in the Analytical Laboratory A Life Cycle Approach Paresh Patel Director, Scientific Operations Johnson& Johnson QS&S 12/14/2016 1 1 Topics GMP regulatory requirements
More informationCross-walk between EU Annex 11 and US FDA 211, 820, 11; other guidelines and regulations Orlando López Rev11AUG16
Principle. a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill
More informationImplementing Compliant Medical Device Best Practice Business Processes Using Oracle E-Business Suite
Implementing Compliant Medical Device Best Practice Business Processes Using Oracle E-Business Suite A white paper discussing the compliant use of the Oracle Electronic Record, Electronic Signature (E-Records)
More informationQ&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document
Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document March 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 ICH Q7 - Questions
More informationStandard operating procedures revisited: a 2014 perspective
Pharmaceutical Pharm. Bioprocess. (2014) 2(1), 41 47 Standard operating procedures revisited: a 2014 perspective Approximately 50 years after the good manufacturing practice (GMP) regulations were first
More informationIT Compliance in the FDA Regulated Industry. IT Responsibilities 10 Years Ago TODAY! 11/17/2008. Business. Security. Compliance. IT & Automation Forum
IT Compliance in the FDA Regulated Industry IT & Automation Forum November 13, 2007 Caribe Hilton, San Juan Puerto Rico Speaker: Mr. Juan O. Pérez, Principal Consultant joperez@fdcpr.com IT Responsibilities
More informationGLP Computerized Systems Updates from OECD Guidance. Dr. Michael Regehr, BASF Corporation 28 JAN 2016, NAICC, Orlando
GLP Computerized Systems Updates from OECD Guidance Dr. Michael Regehr, BASF Corporation 28 JAN 2016, NAICC, Orlando 1 Validation EPA GLP Obligation Expectations of the EPA for Computers in GLP (40 CFR
More informationComputerised System Validation
Computerised System Validation Considerations for the Validation Lifecycle Paul Moody GMP Conference 12 th November 2014 Regulatory References EU GMP Annex 11 (2011) http://ec.europa.eu/health/files/eudralex/vol-4/annex11_01-2011_en.pdf
More informationAudits and Inspections
Audits and Inspections Dr. Dirk Feldmann 06. November 2017 First we take measurements, then we take measures. TECHNICAL Content Audits and inspections Types of audits EHS Challenges and chances Preparation
More informationOECD Working Group on Good Laboratory Practice. Template for submission of comments on draft GLP Guidance Documents. Instructions for Use
OECD Working Group on Good Laboratory Practice Template for submission of comments on draft GLP Guidance Documents Instructions for Use 1. First, please complete the table below giving the full name of
More informationWhite paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU
White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU Numerous articles are available comparing the current and previous EU Code of GMP Chapter 4: Documentation, but no comparison exists between
More informationREXS. Risk Expert System
REXS Risk Expert System REXS by experts for experts REXS is based on the extensive experience of VTU experts in the GMP and safety sector. The system is specifically designed to support experts engaged
More informationInformation Governance for Data Integrity
Information Governance for Data Integrity Presented by: Kip Wolf of Tunnell Consulting Information Systems Track, Session #: SES305 Tuesday 31 OCT 2017 11:40 12:05 Discussion Topics Recent trends in FDA
More information10 "Must-Haves" for the Life Sciences Learning Management System
10 "Must-Haves" for the Life Sciences Learning Management System Why the Life Sciences LMS Needs to Demonstrate Record Control UL talks to many Life Sciences companies that are exploring learning and development
More informationGMP In-house Training
Your benefits: Customised to fit your company s requirements - cost-effective and flexible! GMP In-house Training for the Pharmaceutical, API and Medical Device Industry We offer practice-oriented GMP
More informationBy Dr. Michael Hiob, Max Lazar, Dr. Christian Gausepohl and Dr. Christine Oechslein. Preparing for the EU GMP Inspection
By Dr. Michael Hiob, Max Lazar, Dr. Christian Gausepohl and Dr. Christine Oechslein Preparing for the EU GMP Inspection ISBN: 978-3-943267-79-2 A Process Approach to Pharmaceutical Quality Systems A Guide
More informationTHE COMPLETE GUIDE TO ISO14001
THE COMPLETE GUIDE TO ISO14001 1. Introduction... 3 Plan Do Check Act... 5 2. Requirements... 7 Environmental Policy... 7 Environmental Aspects... 7 Legal and Other Requirements... 8 Objectives & Targets...
More informationVince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016
Quality Management in a Virtual Environment Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Biosimilars - the second wave of biotech -an evolving regulatory
More informationPAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland
PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec 2004 Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland cca@iol.ie 1 FDA Context 1) FDA 5-Part Strategic Plan Protect &
More information21 CFR Ch. I ( Edition) Personnel Design controls Identification Traceability.
Pt. 820 device together with an explanation of the basis for the estimate; (iv) Information describing the applicant s clinical experience with the device since the HDE was initially approved. This information
More informationCompliance Response Electronic Records / Electronic Signatures (ERES) for SIMATIC PCS 7 V8.1
Compliance Response Electronic Records / Electronic Signatures (ERES) for SIMATIC PCS 7 V8.1 SIEMENS AG Industry Sector VSS Pharma D-76187 Karlsruhe, Germany E-Mail: pharma@siemens.com March 2015 A5E35829023-AA
More informationData Integrity: A Structural Approach for Sustainable Outcomes
Data Integrity: A Structural Approach for Sustainable Outcomes John C. (Jack) Garvey, Esq. Founder / Chief Executive Officer Compliance Architects LLC 2017 Pharmaceutical Quality Congress Speaker Introduction
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationData Integrity in Clinical Trials the Sponsor Perspective
Data Integrity in Clinical Trials the Sponsor Perspective Maximilian Stroebe, GSK Vaccines Three differences to Commercial Manufacturing Long process chains Source Data, Clinical Sites and Outsourcing
More informationDesign Qualification SOP
1.0 Commercial in Confidence 16-Aug-2006 1 of 13 Design Qualification SOP Document No: SOP_0400 Prepared by: David Brown Date: 16-Aug-2006 Version: 1.0 1.0 Commercial in Confidence 16-Aug-2006 2 of 13
More informationISO 22000:2005 Standard INTERNATIONAL STANDARDS REGISTRATIONS
ISO 22000:2005 Standard Food Safety Management System INTERNATIONAL STANDARDS REGISTRATIONS 3.1 FOOD SAFETY concept that food will not cause harm to the consumer when it is prepared and/or eaten according
More informationAgenda. 16:00 16:10 Velkommen 16:10 16:15 Inspektion, hvad er det?
Agenda 16:00 16:10 Velkommen 16:10 16:15 Inspektion, hvad er det? 16:15 17:15 Electronic systems for handling of: Source data Data collection tools 17:15 17:45 Pause og networking 17:45 18:30 Trial Master
More informationWHO Prequalification Team (WHO-PQT) Introduction to medicines inspections technical updates
Joint UNICEF, UNFPA & WHO meeting with manufacturers and suppliers of diagnostic products, vaccines, finished pharmaceutical products and active pharmaceutical ingredients WHO Prequalification Team (WHO-PQT)
More informationINS QA Programme Requirements
Specification Date: 20/3/17 INS QA Programme Requirements UNCONTROLLED WHEN PRINTED Author: J Cooch AUTHORISATION Date: 20/3/17 A Brown Owner: J Cooch (Signature) N.B. only required for hard copy If issued
More informationISPE GAMP, leading the way to Productive Compliance
ISPE GAMP, leading the way to Productive Compliance AUTHOR: Chris Reid, Chair ISPE GAMP Europe As well as presenting ISPE GAMP principles and practices for effective regulatory compliance, this White Paper
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationQP s experience with QRM. Fergus O Connell QA Manager AMS Laboratories
QP s experience with QRM Fergus O Connell QA Manager AMS Laboratories December 2011 Risk Management in a QPs role Validation Master Plan Risk Review Early issues Human Error Risk Influencing Factors EU
More informationGMP On Site Series. GMP Essentials
GMP On Site Series GMP Essentials GMP Basics Objectives 1. State the critical definitions of the pharmaceutical industry. 2. Describe the law as it applies to various critical functions. 3. State the history
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationQuality Agreements and Managing Contract Supplier Quality
Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract
More informationENVIRONMENTAL LABORATORY APPROVAL PROGRAM CERTIFICATION MANUAL DATE 5/06/08
1 of 69 Preface The New York State Department of Health, Wadsworth Center, Environmental Laboratory Approval Program (ELAP) has adopted as its Standard the current version of the National Environmental
More informationQUALITY MANAGEMENT SYSTEM POLICIES AND PROCEDURES
Your Company Name QUALITY MANAGEMENT SYSTEM POLICIES AND PROCEDURES Origination Date: XXXX Document Identifier: Date: Document Revision: QMS-00 QMS Policies and Procedures Latest Revision Date Abstract:
More informationThe Impact of Quality Culture on Quality Risk Management. FDA Perspective on Quality Culture; how it Impacts Risk Management
The Impact of Quality Culture on Quality Risk Management FDA Perspective on Quality Culture; how it Impacts Risk Management Teresa Gorecki Practice Lead Compliance Architects Agenda The WHAT Definitions
More informationJean Guichard. Introduction to Good Process Record Management (GxP) #: Internet-WP Version: e1.00 /EN
Jean Guichard White Paper Introduction to Good Process Record Management (GxP) #: Internet-WP Version: e1.00 /EN Introduction to Good Process Record Management (GxP) 2 / 6 Document History Version Date
More informationPART 820 QUALITY SYSTEM REGULATION. 21 CFR Ch. I ( Edition)
814.126 (b) Withdrawal of IRB approval. A holder of an approved HDE shall notify FDA of any withdrawal of approval for the use of a HUD by a reviewing IRB within 5 working days after being notified of
More informationCompliance Response Electronic Records / Electronic Signatures for COMOS V10.0
Compliance Response Electronic Records / Electronic Signatures for COMOS V10.0 SIEMENS AG Industry Sector I IA VSS Pharma D-76187 Karlsruhe, Germany E-mail: pharma@siemens.com November 2013 SIEMENS AG
More informationGuidance for Industry - Computerized Systems Used in Clinical Trials
Page 1 of 14 Regulatory Information Computerized Systems Used in Clinical Trials Guidance for Industry - Computerized Systems Used in Clinical Trials
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More informationQuality Assurance Policy and Procedures
650 Montana Ave, Suite A Las Cruces, NM 88001 (575) 522-0430 www.rmgovernmentservices.com Quality Assurance Policy and Procedures PURPOSE. The purpose of this policy is to outline the quality assurance
More informationCompliance Program Effectiveness Guide
Compliance Program Effectiveness Guide June 2017 This Guide is a comparison of: Compliance Program Elements New York State, Social Services Law 363-D Office of Inspector General (OIG) Compliance Program
More informationQuality Systems. Indian Pharmaceutical Alliance. Advanced GMP Workshops 2017
Quality Systems Indian Pharmaceutical Alliance Advanced GMP Workshops 2017 Presented by Patrick Costello on November 2017 Principal Scientific Administrator Manufacturing & Quality Compliance An agency
More informationGMPs: Distribution Centers
SkillsPlus International Inc. The On-Site Series GMPs: Distribution Centers Learn to apply the GMP regulations as they relate to distribution center operations! FDA Past, Present, and Future and opener
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationCOMPUTER SYSTEMS VALIDATION
COMPUTER SYSTEMS VALIDATION DOCUMENT NO.: POL007 v1.0 AUTHOR: Lorn Mackenzie ISSUE DATE: 04 AUG 2017 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research & Development (ACCORD) is a joint
More informationASQ FD&C GMP Quality Conference
ASQ FD&C GMP Quality Conference End User Testing for Performance Qualification of GXP/ Part 11 Systems Off The Shelf (OTS) Dr. Teri Stokes, GXP International, Concord, MA USA www. GXPInternational.com
More information2015 PDA/FDA Joint Regulatory Conference September 28-30, 2015 Renaissance Washington, DC Downtown Hotel Washington, DC
P3: Integrity By: Monica Cahilly Integrity Training Lessons Learned & Case Studies Monica J. Cahilly, M.S. Green Mountain Quality Assurance LLC www.greenmountainqa.com OUTLINE What is Integrity? Good Documentation
More informationSoftware Quality Regulatory Trends
Software Quality Regulatory Trends By Praxis Life Sciences 1925 West Field Court, Suite 125, Lake Forest, IL 60045 praxislifesciences.com +1(847) 295-7160 validationcenter.com Software Quality Regulatory
More informationFood and Drug Administration, HHS Pt Sec Scope Definitions Quality system.
Food and Drug Administration, HHS Pt. 820 authorized designee. If, however, a physician in an emergency situation determines that approval from an IRB cannot be obtained in time to prevent serious harm
More informationChapter 2 GALP Implementation Assistance
Chapter 2 GALP The GALP Implementation is based on established data management principles. 1. PRINCIPLES Control is the essential objective behind most data management principles. Effective management
More informationZOLL Document Number: 90E0021 Page 6 of 50 QUALITY SYSTEM MANUAL ZOLL Document Number: 90E0021 Page 7 of 50 1 EXECUTIVE MANAGEMENT APPROVAL... 10 2 INTRODUCTION... 11 3 QUALITY SYSTEM... 12 3.1 QUALITY
More informationThe long anticipated draft of the FDA s
This article provides an overview of the draft guidance, the key changes in relation to the 1987 guidance, and reviews its potential impact on the current industry approaches to science- and risk-based
More informationHow Pharma Should Monitor itself for GMP Compliance & How FDA Inspections Could Incorporate Pharmaceutical Inspection Cooperation Scheme (PIC/S)
How Pharma Should Monitor itself for GMP Compliance & How FDA Inspections Could Incorporate Pharmaceutical Inspection Cooperation Scheme (PIC/S) ASQ Northeast Pharmaceutical GMP/Quality Conference January
More informationReduce paper-based errors
December 2008 Page 1 Reduce paper-based errors The Syncade Application eliminates the need for paper-based documentation. It enables quick, easy access to electronic information - when it is needed, where
More informationQ10 PHARMACEUTICAL QUALITY SYSTEM
Q10 PHARMACEUTICAL QUALITY SYSTEM This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights
More informationPTC s Windchill Product Lifecycle Management (PLM) System Facilitates Part 11 / Annex 11 Compliance
PTC s Product Lifecycle Management (PLM) ystem Facilitates Part 11 / Annex 11 Compliance A White Paper by: Diane Gleinser, r. VP olutions and ervices, UDM Life ciences Michael Prudhomme, olution Director,
More informationQuality Manual. Index
This quality policy manual is for the use of, its Clients, Vendors, and the appropriate Regulatory Agencies. Unauthorized duplication or transfer to others is prohibited. Index Authorization... 3 Introduction...
More informationSeamless Integration of ASTM E2500, Annex 15, FDA Process Validation Guideline and Chinese GMP in Large CapEx Project in China Daniel Nilsson
Seamless Integration of ASTM E2500, Annex 15, FDA Process Validation Guideline and Chinese GMP in Large CapEx Project in China Daniel Nilsson Senior Management Consultant Agenda Introduction A state-of
More informationAAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward, Owner, Ward Sciences
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationSarbanes-Oxley Compliance Kit
Kit February 2018 This product is NOT FOR RESALE or REDISTRIBUTION in any physical or electronic format. The purchaser of this template has acquired the rights to use it for a SINGLE Disaster Recovery
More informationMedical Device Purchasing Controls Challenges of Compliance in a World Market June, 2013 OMTEC
Medical Device Purchasing Controls Challenges of Compliance in a World Market June, 2013 OMTEC - 2013 Quality Business Acceptance Activities 1 ..FDA Across the Globe.. 2 ..Warning Letters and FDA 483 update..
More informationRegulations and guidance for the pharmaceutical industry
w w w. spec troscopyonline. com April 2011 Spectroscopy 26(4) 1 Focus on Quality Is GMP Annex 11 Europe s Answer to 21 CFR 11? January 2011 saw the publication of the new revision of European Union (EU)
More informationISO Monitoring and Measurement Nonconformance and Corrective and Preventative Action
ISO 14001 4.5.1 Monitoring and Measurement 4.5.2 Nonconformance and Corrective and Preventative Action 4.5.1 Monitoring and Measurement The organization shall establish and maintain documented procedures
More informationREPORT 2016/067 INTERNAL AUDIT DIVISION. Audit of management of national staff recruitment in the United Nations Assistance Mission for Iraq
INTERNAL AUDIT DIVISION REPORT 2016/067 Audit of management of national staff recruitment in the United Nations Assistance Mission for Iraq Overall results relating to the effective management of national
More informationChristian Gausepohl, Frank Böttcher. GMP Focus. Managing Contract Manufacturers and Testing Labs. PDF Download. Excerpt from the GMP MANUAL
Christian Gausepohl, Frank Böttcher GMP Focus Managing Contract Manufacturers and Testing Labs PDF Download Excerpt from the GMP MANUAL Bibliographic Data of the Deutsche Nationalbibliothek: http://dnb.ddb.de
More informationRisk-Based Approach to Software Quality and Validation
Risk-Based Approach to Software Quality and Validation By Praxis Life Sciences 1925 West Field Court, Suite 125, Lake Forest, IL 60045 praxislifesciences.com +1(847) 295-7160 validationcenter.com Risk
More informationVersion 1.0 August 30, 2017
Supplier Requirements Guideline 1.0 Purpose The purpose of this Supplier Requirements Guideline is to provide a guidance document with the expectations and requirements Baxter has of its suppliers. The
More informationImplementation Life-cycle SOP
1.0 Commercial in Confidence 11-Aug-2006 1 of 12 Implementation Life-cycle SOP Document No: H4_SOP_0100 Prepared by: David Brown Date: 11-Aug-2006 Version: 1.0 1.0 Commercial in Confidence 11-Aug-2006
More informationTextvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf
Textvergleich Verglichene Dokumente MEDIA3917.pdf ICH_Q10_Step4.pdf Übersicht 2270 Wort/Wörter hinzugefügt 1338 Wort/Wörter gelöscht 3558 Wort/Wörter übereinstimmend 157 Block/Blöcke übereinstimmend Blättern
More informationSection 1: Purpose & Objectives of PCI 3000 Certification Program
The Powder Coating Institute PCI 3000 Certification Program Revised 7/7/2014 Any copy, reproduction or unauthorized distribution of this material without written consent from The Powder Coating Institute
More informationImpact of WHO Guidelines on GMP for Blood Establishments
Impact of WHO Guidelines on GMP for Blood Establishments Christian Schärer, Ph.D. Swissmedic, Swiss Agency for Therapeutic Products, Head Inspectorate International Conference of Drug Regulatory Authorities
More informationHow to support compliance with GAMP 5
PRESENTATION How to support compliance with GAMP 5 KERESZTESI Kálmán Controsys Irányítástechnikai Kft. kalman.keresztesi@controsys.hu Agenda What is GAMP 5 about? Application Lifecycle Management in automation
More information